Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ÂčâžF-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ÂčâžF-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
Inclusion Criteria:
Exclusion Criteria:
Box Hill, 3128, Australia
Chermside, 4032, Australia
Darlinghurst, 2010, Australia
Erina, 2250, Australia
Glen Iris, 3146, Australia
Heidelberg, 3084, Australia
Herston, 4029, Australia
Nedlands, 6009, Australia
Parkville, 3050, Australia
West Perth, 6005, Australia
Gatineau, J8T 8J1, Canada
Ottawa, KIN 5C8, Canada
Verdun, H4H 1R3, Canada
Akashi, 673-0891, Japan
HachiĆji, 193-0998, Japan
Ikeda, 563-0058, Japan
Kasukabe-shi, 344-0036, Japan
Kyoto, 606-0851, Japan
Nagoya, 451-8511, Japan
Nerima-ku, 179-0072, Japan
Osaka, 533-0004, Japan
Osaka, 559-0004, Japan
Setagaya-ku, 158-8531, Japan
Takamatsu, 760-8557, Japan
Tokyo, 156-0041, Japan
Wako, 351-0111, Japan
Yokosuka-shi, 238-0042, Japan